The primary dermal irritation potential of diethyleneglycol dinitrate (DEGDN) was ieternuned in New Zealand White rabbits using a modified Draize procedure. The test compound was classified as a nonirritant following a 4-hour application period. Neither edema, erythema, nor any other recognizable skin reaction was detected at any time during ri,-72-hour observation period.- 
PREFACE

INTRODUCTION
The Department of Defense is considering the use of either diethyleneglycol dinitrate (DEGDN), triethyleneglycol dinitr te (TEGDN) , or trimethylolethane trinitrate (TMETN) as a rep; ~ement for nitroglycerin in new propellant formu: .-itions. However, considerable gaps in the toxicology data ;; the compounds were identified during a review of their r.ealth effects !l) conducted for the US Army Biomedical Reseat or. and Development Laboratory (USABRDL) . Consequently, USABR: ■ -has tasked the Division of Toxicology, Letcerman Army Instit ;:e of Research (LAIR), to conduct an initial health effect 1 , evaluation of the proposed replacement nitrate esters. This initial evaluation of DEGDN, TMETN, TEGDN, and two DEGDN-based propellants, JA-2 and DIGL-RP, includes the Ames :T O agenicity assay, acute oral toxicity r ests in rats and mice, acute dermal toxicity in rabbits, dermal and ocular irritation studies in rabbits, and dermal sensitization studies in guinea pigs. . i
Molecular structure
O2N--O--CH2CH2-O-CH2CH2-O-NO2
Molecular Formula: C.;HgN207
Other test substance information is presented in Appendix A. 
METHODS
Acclimation and Group Assignment
Study animals were initially assigned to GLP study 85029 for 25 days following a 14-day quarantine by the Division of Animal Care and Services. They were treated once prophylactically for ear mites with Canex® and mineral oil while under quarantine. During this period they were observed daily for signs of illness; they were not dosed. On 19 Aug 85, the animals were transferred to GLP study 85004, clipped, and quadrants marked. On 20 Aug 85, the animals were dosed.
Dosaoe Levels
A standard dose of 0.5 ml DEGDN was used for the test compound sites.
Compound Preparation
The test compound was received as a solution containing 18% acetone. The acetone was removed by evaporation before studies with the propellant (Appendix A).
Chemical Analysis of Dosing Solution DEGDN was analyzed for purity and stability (Appendix A). The reformulated DEGDN was sufficiently pure and stable for use in the test procedures.
Test Procedures
This study was conducted in accordance with EPA guidelines (2) and LAIR SOP-OP-STX-34 (3).
The backs of six rabbits were close-clipped 24 hours before dosing and divided into four unabraded quadrants designated I-IV '^,5). Each animal had two sites (II, III) treated with the test compound. Site I was a sham control (no treatment) site and site IV a sham gauze patch control. A dose of 0.5 ml of DEGDN was placed on a 1-inch square gauze patch which was taped to the appropriate site. Blenderm® (Medical Products Division of 3M, St Paul, MN), a semiimpervious hypoallergenic surgical tape, was used to hold the patches in place. Vetrap® (Animal Care Products Division of 3M, St. Paul, MN) was then wrapped securely around the animal. The test compound was left in contact with the skin for 4 hours. At the end of the exposure period, the wrapping and patches were removed and the skin was gently wiped if the test rraterial had adhered to it, and the areas were scored one hour later.
Observations
The grading and scoring for dermal reactions were performed according to Table 1 (4). Scoring and grading of Possible total erythema score 4
Edema Formation
No edema 0 Very slight edema (barely perceptible) 1 Slight edema (edges of area well-defined by definite raising) 2 Moderate edema (edges raised approx. 1 mm) 3 Severe edema (raised more than 1 mm and extending beyond area of exposure) 4
Possible total edema score 4
Possible total score for primary irritation 8
"Any skin reaction more serious than severe edema, vesiculation, ulceration, or necrosis places the chemical in Category V.
dermal reaction were performed at 1, 24, 48, and 72 hours after removal of the patches. Routine observations for clinical signs were made daily from 20 Aug to 3 Sep 85.
Duration of Study
Appendix C is a complete listing of historical events.
Changes/Deviations from Original Protocol
This study was conducted in accordance with applicable SOPs, the protocol, and addenda, excepting the sex of the animals included both males (6) and females (2) rather than all females. This deviation did not affect the outcome of this study.
Storage of the Raw Data and Final Report
A copy of the final report, study protocols, raw data, retired SOPs, and an aliquot of the test compound will be retained in the LAIR Archives.
RESULTS
Results from scoring the dermal irritation in each rabbit are tabulated in Appendix D. All scores were negative. Neither edema, erythema, nor any other recognizable skin reaction was detected at any time during the 72-hour observation period.
The six dosed animals were submitted for gross necropsy on 3 Sep 85. There were no signs of skin irritation in any of the animals. The Veterinary Pathologist's Report is presented as Appendix E.
DISCUSSION
The modified Draize dermal irritation test as performed for this study has proven reliable for detecting nonirritating substances and severe irritants but considerably less reliable for detecting mild and moderate irritants (5). Consequently, many systems have been used to score and categorize the dermal irritation potentials of a test compound. The system used by the Division of Toxicology, LAIR, is an adaptation of one used at the US Army Environmental Hygiene Agency (6) . It develops a dermal irritation indent based on the peak net mean score, which is the maximum net mean score calculated during the 72-hour Topically applied DEGDN produced neither edema nor erythema at any test site on six rabbits. Also, all sham sites were negative for dermal reactions. Therefore, the Peak Net Mean Score for DEGDN was zero. Based on these findings, DEGDN was classified as a nonirritant.
CONCLUSION
Diethyleneglycol dinitrate (DEGDN) should be classified as a nonirritant since it causes no grossly detectable dermal reactions under conditions of this study. 
